Patents by Inventor Kitt Petersen

Kitt Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-invasive assessment of hepatic mitochondrial metabolism by positional isotopomer NMR tracer analysis (PINTA)
    Patent number: 11484608
    Abstract: The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-13C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 1, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Gerald I. Shulman, Rachel Jamison Perry, Gary Cline, Douglas Rothman, Kitt Petersen
  • Non-Invasive Assessment of Hepatic Mitochondrial Metabolism by Positional Isotopomer NMR Tracer Analysis (PINTA)
    Publication number: 20200246490
    Abstract: The present provides a Positional Isotopomer NMR Tracer Analysis (PINTA) method that can be used to noninvasively assess rates of hepatic mitochondrial oxidation (VCS) and/or pyruvate carboxylase (VPC) flux in a subject. In certain embodiments, the methods utilize a combined NMR/gas chromatography-mass spectrometry analysis of plasma following infusion of [3-13C]lactate and glucose tracer. The method of the invention provides investigators with a tool to non-invasively examine the role of altered hepatic mitochondrial metabolism and study the effects of therapeutic interventions for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and type 2 diabetes (T2D).
    Type: Application
    Filed: October 5, 2018
    Publication date: August 6, 2020
    Inventors: Gerald I. Shulman, Rachel Jamison Perry, Gary Cline, Douglas Rothman, Kitt Petersen